Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Non-Hodgkin's Lymphoma: Update Bulletin #1 [December 2018]

Product Code:
596201066
Publication Date:
December 2018
Format:
PDF
Price:
$1,315

This edition presents key opinion leader (KOL) views on recent developments in the non-Hodgkin’s lymphoma (NHL) market. Topics covered include: Unum Therapeutics announcing that it expects to complete enrolment in its Phase I (ATTCK-20-03) clinical trial evaluating ACTR707, an antibody-coupled T cell receptor construct made from the patient's own T cells, combined with rituximab (Rituxan/MabThera; Roche), in patients with relapsed/refractory CD20-positive B cell NHL in H1 2019; Nordic Nanovector announcing a presentation of updated results from its LYMRIT 37-01 Phase I/II clinical study of Betalutin (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory indolent non-Hodgkin's lymphoma at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, CA, USA; and TG Therapeutics reporting successful enrolment of the first cohort evaluating TG-1701, a novel, orally available and covalently-bound Bruton tyrosine kinase inhibitor, in the Phase I study for patients with relapsed or refractory B-cell malignancies.

Business Questions:

• What is the potential of ACTR707 + rituximab as a future treatment of NHL?
• What place does ACTR707 + rituximab have in the treatment paradigm?
• What are the safety concerns with Betalutin?
• What are the experts’ opinions on the main barriers to Betalutin’s uptake?
• What role will TG-1701 play, either alone or in combination, in the future treatment of NHL?
• What concerns do KOLs have regarding the combination of TG-1701 with ublituximab and umbralisib?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved